235 related articles for article (PubMed ID: 35846211)
1. Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.
Fazio F; Franceschini L; Tomarchio V; Rago A; Garzia MG; Cupelli L; Bongarzoni V; Andriani A; Gumenyuk S; Tafuri A; Siniscalchi A; Piciocchi A; De Fabritiis P; De Rosa L; Caravita di Toritto T; Annibali O; Cantonetti M; Petrucci MT
EJHaem; 2022 Feb; 3(1):121-128. PubMed ID: 35846211
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
3. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'.
Mele G; Cascavilla N; Di Renzo N; Guarini A; Mazza P; Melillo L; Pavone V; Tarantini G; Curci P; Falcone AP; Germano C; Mele A; Palazzo G; Palumbo G; Reddiconto G; Rossini B; Specchia G; Musto P; Pastore D
Ann Hematol; 2022 Aug; 101(8):1727-1739. PubMed ID: 35587825
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from
Duarte PJ; Schutz NP; Ochoa P; Yantorno S; Orlando S; Lopresti S; Zabaljauregui S; Aizpurua F; Shanley C; Giannini E; Garate G; Foncuberta C; Milone J; Riveros D; Fantl D
Expert Rev Hematol; 2021 Mar; 14(3):315-322. PubMed ID: 33541156
[TBL] [Abstract][Full Text] [Related]
9. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Liu J; He HY; Li L; Lu J; Qiang WT; Guo P; Hou N; Jiang H; Du J; Fu WJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):27-32. PubMed ID: 33677865
[No Abstract] [Full Text] [Related]
10. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Alhaj Moustafa M; Parrondo R; Abdulazeez MF; Roy V; Sher T; Alegria VR; Warsame RM; Fonseca R; Rasheed A; Gonsalves WI; Kourelis T; Kapoor P; Buadi FK; Dingli D; Hayman SR; Reeder CB; Chanan-Khan AA; Ailawadhi S
Anticancer Drugs; 2024 Jan; 35(1):63-69. PubMed ID: 37067996
[TBL] [Abstract][Full Text] [Related]
11. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
Sonneveld P; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Levin MD; Ahmadi T; Qin X; Garvin Mayo W; Gai X; Carey J; Carson R; Spencer A
J Clin Oncol; 2023 Mar; 41(8):1600-1609. PubMed ID: 36413710
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
13. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Ahmadi T; Qin X; Garvin Mayo W; Gai X; Carey J; Carson R; Moreau P
J Clin Oncol; 2023 Mar; 41(8):1590-1599. PubMed ID: 36599114
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple Myeloma.
Afrough A; Atrash S; Paul B; Ouchveridze E; Ahmed N; Mahmoudjafari Z; Bashir A; Alkharabsheh O; Hashmi H; Abdallah AO
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835587
[TBL] [Abstract][Full Text] [Related]
15. A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Furlan A; Cea M; Pavan L; Galli M; Clissa C; Mangiacavalli S; Cafro AM; Girlanda S; Patriarca F; Minotto C; Bertoldero G; Barilà G; Pascarella A; Lico A; Paolini R; Rabassi N; Pescosta N; Porrazzo M; De Sabbata G; Pompa A; Bega G; Cavallin S; Guidotti F; Marcatti M; Rupolo M; Belotti A; Gherlinzoni F; Zambello R
Cancer Med; 2024 Apr; 13(7):e7071. PubMed ID: 38558233
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experience.
Fucci L; Gensini L; Coppetelli U; La Barbera EO; Gentile M; Fiori L; Perrone S; Cimino G
Leuk Res Rep; 2022; 17():100330. PubMed ID: 35694449
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.
Mian H; Eisfeld C; Venner CP; Masih-Khan E; Kardjadj M; Jimenez-Zepeda VH; Khandanpour C; Lenz G; McCurdy A; Sebag M; Song K; LeBlanc R; White D; Stakiw J; Reiman A; Louzada M; Aslam M; Kotb R; Gul E; Reece D
Front Oncol; 2022; 12():826342. PubMed ID: 35251992
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
19. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.
Harvanová Ľ; Štulajterová V; Guman T; Ladická M; Hlebašková M; Chudej J; Šimek M; Štecová N; Flochová E; Kubala J; Simančíková I; Drgoňa Ľ; Vranovský A; Wild A; Mistrík M; Bátorová A
Neoplasma; 2021 May; 68(3):626-630. PubMed ID: 33567854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]